Howard Chang , M.D., Ph.
D., Joins as Senior Vice President of Research and Chief Scientific Officer THOUSAND OAKS, Calif. , Nov.
20, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced that Howard Chang , M.D., Ph.
D., will join the company as senior vice president of Research, effective Dec. 16, 2024 .
Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay Bradner , M.D., executive vice president of Research and Development.
"Howard is one of our generation's foremost physician-scientists, with expertise in human genetics and a profound ability to distill complex disease biology into clarified targets," Bradner said. "Leading Research at Amgen is a vital role that shapes the disease-altering therapies we pursue for patients. Howard's high-technology approach to science, coupled with his groundbreaking research in gene control, cancer biology and stem cell biology, complements the work we do every day.
" Chang will be responsible for establishing and leading all research priorities within Amgen's rare disease, oncology, inflammation and cardiometabolic therapeutic areas. He will also oversee operations in key research hubs from San Francisco to Thousand Oaks , and across the company's global network of specialized sites in Reykjavik , Copenhagen , Munich , British Columbia , and Maryland . Chang succeeds the highly distinguished Ray Deshaies , Ph.
D., former senior vice president of Research, whose departure wa.
